Skip to main content
JPAM_logo
  • Funds

    Fund Listing

    • Fund Explorer
    • Fund Distribution
    • Fund Documents

    Featured Funds

    • Sustainable Infrastructure Fund
    • Income Fund
    • Multi Income Fund
    • Future Transition Multi-Asset Fund
    • Global Equity Solutions
    • China Income and Growth Solutions
  • Insights

    Market Insights

    • Market Insights Overview
    • Guide to the Markets
    • Weekly Market Recap
    • On the Minds of Investors
    • Guide to China
    • Multimedia

    Portfolio Insights

    • Portfolio Insights Overview
    • Long-Term Capital Market Assumptions
    • Global Asset Allocation Views
    • Global Fixed Income Views

    Retirement Insights

    • Retirement Insights Overview
    • Principles for a Successful Retirement
    • Building Better Retirement Portfolios
    • Are you letting volatility derail your retirement plan?
  • Investment Ideas
    • Managing Volatility
    • Growth Strategy
    • Income Strategy
    • Retirement and long-term investing
    • Sustainable Investing
  • Resources
    • Announcements
    • Forms & Literature
    • Investment Glossary
    • Library
    • Insights App
  • About Us
    • Awards
  • Partner With Us
  • Language
    • English
    • 中文/ Chinese
  • Role
  • Country
  • Search
    Search
    Menu
    1. Spotlight on healthcare investing: is the smart pen mightier than the sword?

    Spotlight on healthcare investing: is the smart pen mightier than the sword?

    Dec 2021 (3-minute read)

    J.P. Morgan Asset Management

    Key takeaways:

    • Governments and companies have increased investments in healthcare, presenting long-term growth opportunities in sub-sectors such as medical technologies, devices and services, alongside biotechnology and pharmaceuticals1.

    How smart can a pen be2 ?

    Pens are no longer used only for writing in the healthcare sector. And some pens have become smarter.

    Innovative medical devices such as a smart, reusable insulin pen2 is improving the quality of life for patients with diabetes. It’s a pen that offers quick and relatively painless injections, can calculate and track doses as well as provide reminders, alerts and reports. When connected to a smartphone app, the pen could also help diabetics better monitor their blood sugar levels, diet and exercise. The data on the pen could also help doctors and patients make optimial treatment decisions.

    Additionally, some healthcare companies are using data science and artificial intelligence for new medicines and timely diagnosis. Such breakthrough in treatments and innovative technologies are presenting long-term growth opportunities in the healthcare sector.

    JPMorgan Funds - Global Healthcare Fund

    Investing in healthcare - same, same but different1

    • What hasn’t changed. Long-term structural themes such as innovation, demographics, mergers & acquisitions as well as rising demand in emerging markets have remained intact in the healthcare industry. Such trends have continued to bolster the earnings profile, valuations and alpha-generating opportunities of some healthcare companies.

    • What has changed. Since the onset of the global public health crisis, investor interest in the healthcare sector has been on the rise, alongside public debate over the efficacy of vaccines used in the treatment of infectious diseases. The industry has also seen some breakthroughs in treatments with the increased use of innovative technologies.

    What to keep in mind


    A digital transformation of healthcare is taking place across all members of the Organization for Economic Co-operation and Development (OECD) grouping, accelerated by the public health crisis and driven up by digitisation of IT infrastructure as well as growing demand from patients3. Additionally, a rapid rise in demand among emerging markets could help accelerate the sector’s long-term growth.


    Forward P/E of US healthcare sectors and the S&P 5004

    Governments and companies have accelerated investments in healthcare, including sub-sectors such as innovative medical technologies, biotechnology, pharmaceuticals and new medical devices and services. As illustrated in the chart4, these various healthcare sub-sectors, where valuation remains relatively attractive, are presenting long-term growth opportunities.

    OUR GROWTH SOLUTIONS

    JPMorgan China A-Share Opportunities Fund

    JPMorgan Asia Growth Fund

    Our Global Growth Solutions

    Conclusion
     

    The global public health crisis has brought healthcare to the forefront, presenting long-term growth opportunities in sub-sectors such as innovative medical technologies, biotechnology, pharmaceuticals as well as new medical devices and services. Additionally, the growing middle class in emerging markets and an ageing population could help accelerate demand and the sector’s long-term growth.

    Provided for information only based on market conditions as of date of publication, not to be construed as investment recommendation or advice.

    Diversification does not guarantee investment return and does not eliminate the risk of loss.

    1. For illustrative purposes only based on current market conditions, subject to change from time to time. Not all investments are suitable for all investors. Exact allocation of portfolio depends on each individual’s circumstance and market conditions.
    2. Source: “What is a smart insulin pen?”, American Diabetes Association. As of November 2021.
    3. Source: “Health at a Glance 2021: OECD Indicators”, Organisation for Economic Co-operation and Development, 09.11.2021
    4. Source: J.P. Morgan Asset Management’s chart based on data from Bloomberg between 04.01.2013 and 30.09.2021. Forward price-to-earnings (P/E) is next 12 months. Forecasts and estimates are indicative of macro trends, may or may not come to pass. 

    Investment involves risk. Not all investments are suitable for all investors. Past performance is not a reliable indicator of current and future results. Please refer to the offering document(s) for details, including the risk factors. Investors should consult professional advice before investing. Investments are not similar to or comparable with fixed deposits. The opinions and views expressed here are as of the date of this publication, which are subject to change and are not to be taken as or construed as investment advice. Estimates, assumptions and projections are provided for information only and may or may not come to pass. This document has not been reviewed by the SFC. Issued by JPMorgan Funds (Asia) Limited.

    OUR FOCUS FUNDS

    Equity

    • JPMorgan Asia Growth Fund
    • JPMorgan China A-Share Opportunities Fund
    • JPMorgan China Pioneer A-Share Fund
    • JPMorgan Funds - US Technology Fund

    Asset Allocation

    • JPMorgan Multi Balanced Fund
    • JPMorgan Multi Income Fund

    Fixed Income

    • JPMorgan Asian Total Return Bond Fund
    • JPMorgan Funds - China Bond Opportunities Fund
    • JPMorgan Funds – Income Fund
    • JPMorgan Global Bond Fund
    See all funds

    RELATED ARTICLES

    Seeking long-term growth opportunities among the old & new in ASEAN

    ASEAN is gaining momentum with its mix of old & new economies.

    Read more

    Are bonds back as inflation hits the high notes?

    We share our views on the fixed income themes and opportunities in current choppy markets.

    Read more

    What to know about sustainable & traditional infrastructure

    We share a perspective on sustainable and traditional infrastructure.

    Read more

    Eyes on the future: digital education

    Digital education helps enhance the learning experience, driving new growth opportunities.

    Read more

    Investing to help shape a new urban environment

    We discuss how urbanisation is driving opportunities in the infrastructure space.

    Read more

    Climate change: a sustainable investing megatrend

    We discuss five megatrends related to climate change and the investment implications.

    Read more

    Eyes on the future: autonomous vehicles

    The development of autonomous cars creates new investment opportunities.

    Read more

    Eyes on the future: smart cities

    Harnessing innovative digital and communications technologies for new economic growth opportunities.

    Read more

    Turning to Asia in the drive for equity income potential

    Asia is more than a growth story. Find out why Asian dividends are back in the spotlight.

    Read more

    Mapping out an income journey as the winds change

    We share our ideas on how to navigate an income journey as market conditions change.

    Read more

    Investing for a changing world

    We share our perspectives of sustainable investing in an overall portfolio.

    Read more

    Positioning a fixed income portfolio for rising rates? We share 3 pointers

    We share our perspectives on positioning for income as rates rise.

    Read more

    1Q 2022 outlook: bonds still matter even as inflation stays elevated

    We share our views on the bond themes and opportunities for the first quarter of 2022.

    Read more

    Seeking diversification in a ‘prosperity pot’ to help drive income opportunities

    Consider diversity across regions, assets and sectors in an income portfolio.

    Read more

    Emerging growth opportunities when consumption goes ‘all about me’

    We share our views on how increasing demand for personalised products and services presents growth opportunities.

    Read more

    2022 outlook: what’s top of mind for income & growth?

    We share our perspectives on the investment landscape for 2022 and the opportunities for income and growth.

    Read more

    Seeking out income opportunities in dividend stocks amid uncertain times

    Dividend stocks are back on investors’ radar as relatively attractive opportunities are emerging.

    Read more

    Where we see income opportunities as the Fed winds down stimulus

    We share how we employ a flexible approach to tap into income opportunities.

    Read more

    Exploring the role of corporate credit in a diversified portfolio

    Income investors like us have stayed the course as market conditions evolve. Where do we see income opportunities?

    Read more

    4Q 2021 bonds: themes and opportunities as rates look set to rise

    Looking at bonds themes and opportunities in the final quarter of 2021.

    Read more

    From diagnosis to investing: capturing medtech opportunities

    The investing potential of the future world – medical technology

    Read more

    Capturing the potential of the future world as we live smarter in the city

    The investing potential of the future world – smart cities

    Read more

    Securitisation 101: What are ABS and MBS?

    Fixed income isn’t just government or corporate bonds, it also includes non-traditional debt securities.

    Read more

    Securitisation: Then and now

    The securitisation market has regained much ground in the past decade.

    Read more

    The secret to effective diversification

    Diversification sounds easy, but how to do it effectively?

    Read more
    lets-solve-it-logo

    For more information, please call or email us. You can also contact your J.P. Morgan representative.

    (852) 2978 7788

    agents.info@jpmorgan.com

    J.P. Morgan Asset Management

    • Terms of Use
    • Privacy Statement
    • Cookies Policy
    • Investment Stewardship
    • Fund Notes
    • Offering Document(s)
    • Forms & Literature
    • Complaint Resolution
    • Guide to Using This Website
    • Sitemap
    J.P. Morgan

    • J.P. Morgan
    • JPMorgan Chase
    • Chase

    Important: This area of the website is intended only for distributors of JPMorgan Funds (Asia) Limited. Information is not intended for retail or public distribution.

    Investment involves risk. Past performance is not indicative of future performance. In particular, funds which are invested in emerging markets and smaller companies may involve a higher degree of risk and are usually more sensitive to price movements. Investors should carefully read and consider the fund offering document(s), which contain details on investment objectives, risk factors, charges and expenses of the fund, before making any investment decisions. Information in this website does not constitute investment advice, or an offer to sell, or a solicitation of an offer to buy any security, investment product or service, nor a distribution of information for any such purpose. Informational sources are considered reliable but you should conduct your own verification of information contained herein. The above information has not been reviewed by the SFC, issued by JPMorgan Funds (Asia) Limited.

    Copyright 2022 JPMorgan Funds (Asia) Limited. All rights reserved.